Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Oxaliplatin

Oxaliplatin Reactions 1704, p288 - 2 Jun 2018 Anaphylactic shock: case report A 76-year-old woman developed anaphylactic shock during treatment with oxaliplatin for recurrent colon cancer [route not stated]. The woman, who was diagnosed with recurrent colon cancer stage IIIa, started receiving treatment with oxaliplatin 130 mg/m , bevacizumab and capecitabine [Xelox]. No adverse events were noted till the completion of six courses. During the seventh course (after three months of drug holiday), nine minutes following oxaliplatin initiation, she developed nausea and started feeling poorly. The woman’s oxaliplatin treatment was immediately discontinued and oxygen was initiated. Three minutes later, she groaned and lost consciousness. She developed cardiopulmonary arrest and cardiopulmonary resuscitation was started. She received adrenaline. Her heart beat restarted and she was subsequently admitted to the ICU. A diagnosis of anaphylactic shock was made. She was treated with unspecified steroids, chlorphenamine and famotidine. The following day, she was extubated and was discharged on day 8 of illness. After 42 days of the cardiopulmonary arrest, the chemotherapy was re-initiated with bevacizumab and capecitabine. She achieved a complete remission with no further recurrence. Author comment: [Oxaliplatin] is used widely in chemotherapy for colon cancer; however, typical side effects are reported as. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Oxaliplatin

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018

Oxaliplatin

Abstract

Reactions 1704, p288 - 2 Jun 2018 Anaphylactic shock: case report A 76-year-old woman developed anaphylactic shock during treatment with oxaliplatin for recurrent colon cancer [route not stated]. The woman, who was diagnosed with recurrent colon cancer stage IIIa, started receiving treatment with oxaliplatin 130 mg/m , bevacizumab and capecitabine [Xelox]. No adverse events were noted till the completion of six courses. During the seventh course (after three months of drug holiday), nine...
Loading next page...
 
/lp/springer_journal/oxaliplatin-IO69d4xZtK
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46931-3
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p288 - 2 Jun 2018 Anaphylactic shock: case report A 76-year-old woman developed anaphylactic shock during treatment with oxaliplatin for recurrent colon cancer [route not stated]. The woman, who was diagnosed with recurrent colon cancer stage IIIa, started receiving treatment with oxaliplatin 130 mg/m , bevacizumab and capecitabine [Xelox]. No adverse events were noted till the completion of six courses. During the seventh course (after three months of drug holiday), nine minutes following oxaliplatin initiation, she developed nausea and started feeling poorly. The woman’s oxaliplatin treatment was immediately discontinued and oxygen was initiated. Three minutes later, she groaned and lost consciousness. She developed cardiopulmonary arrest and cardiopulmonary resuscitation was started. She received adrenaline. Her heart beat restarted and she was subsequently admitted to the ICU. A diagnosis of anaphylactic shock was made. She was treated with unspecified steroids, chlorphenamine and famotidine. The following day, she was extubated and was discharged on day 8 of illness. After 42 days of the cardiopulmonary arrest, the chemotherapy was re-initiated with bevacizumab and capecitabine. She achieved a complete remission with no further recurrence. Author comment: [Oxaliplatin] is used widely in chemotherapy for colon cancer; however, typical side effects are reported as.

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References